CQN-WA-SPIE
3.6.2021 18:21:06 CEST | Business Wire | Press release
In the bulleted section of the release dated June 2, 2021, all of the references to June should be July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005138/en/
The updated release reads:
RIT AND SPIE PARTNER ON 2021 PHOTONICS FOR QUANTUM EVENT
The program, now in its third year, focuses on how photonic devices are impacting quantum science, technology, and applications
On 12-16 July, SPIE, the international society for optics and photonics, and Rochester Institute of Technology (RIT), will present the 2021 Photonics for Quantum Digital Forum . Previously an RIT initiative, this year marks a new iteration of this event in the form of a partnership between RIT and SPIE.
The five-day event will include more than 20 speakers from across international industry and research as well as an interactive poster session. Discussions and presentations will focus on quantum topics spanning applications, experiments, quantum photonic integrated circuits, materials, integration between dissimilar material systems, devices, and concepts to support a national quantum foundry.
Invited speakers include Qunnect’s Noel Goddard ; the US Air Force Research Laboratory’s Michael Fanto ; Imperial College London’s Ian A. Walmsley ; Eleni Diamanti of Sorbonne University’s Laboratoire d'Informatique de Paris 6; Laboratoire Matériaux et Phénomènes Quantiques’ Sara Ducci ; the University of Birmingham’s Kai Bongs ; and Anton Zeilinger of the University of Vienna and the Institute for Quantum Optics and Quantum Information of the Austrian Academy of sciences.
The Photonics for Quantum program sessions include:
- 12 July: Networks and Communication
- 13 July: Computing and Simulation
- 14 July: Sensing and Imaging
- 15 July: Components
- 16 July: Special events and panels, including Women in Quantum (in conjunction with the SPIE Women in Optics program), global government initiatives and funding, and workforce and education
“RIT is thrilled to partner with SPIE to present this year’s Photonics for Quantum conference,” said Don Figer , director of RIT’s Future Photon Initiative. “For the past two years, this event has provided an important forum to discuss the latest breakthroughs in quantum science and technology, as well as how to unlock this growing field’s potential. We look forward to expanding the conference by accessing SPIE’s worldwide network.”
“We’re very excited to be partnering with RIT on this growing event,” said SPIE Director of Industry Development Stephen Anderson . “It’s a wonderful opportunity to help showcase the fast-emerging field of quantum technology and the exciting possibilities that exist in it for photonics. With its particular focus on scientific and academic content, covering both fundamental research and in-lab developments, Photonics for Quantum is a terrific complement to the industry-focused SPIE Quantum West and a great addition to the SPIE calendar.”
Registration for Photonics for Quantum is now open. Visit our website for more information and to register for the event .
About RIT
Rochester Institute of Technology is home to leading creators, entrepreneurs, innovators, and researchers. Founded in 1829, RIT enrolls 18,600 students in more than 200 career-oriented and professional programs, making it among the largest private universities in the US. The university is internationally recognized and ranked for academic leadership in business, computing, engineering, imaging science, liberal arts, sustainability, and fine and applied arts. RIT also offers unparalleled support services for deaf and hard-of-hearing students . The cooperative education program is one of the oldest and largest in the nation. Global partnerships include campuses in China, Croatia, Dubai, and Kosovo.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom